Molecular Oncology
Volume 2, Issue 3 , Pages 272-281 , October 2008

The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr–Abl activity in chronic myeloid leukemia

  • Oliver Hantschel

      Affiliations

    • Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090 Vienna, Austria
    • O.H. and A.G. contributed equally to this study.
    • ,
  • Agnes Gstoettenbauer

      Affiliations

    • Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090 Vienna, Austria
    • O.H. and A.G. contributed equally to this study.
    • ,
  • Jacques Colinge

      Affiliations

    • Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090 Vienna, Austria
    • ,
  • Ines Kaupe

      Affiliations

    • Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090 Vienna, Austria
    • ,
  • Martin Bilban

      Affiliations

    • Department of Laboratory Medicine, Medical University of Vienna and Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Währinger Gürtel 18–20, 1090 Vienna, Austria
    • ,
  • Thomas R. Burkard

      Affiliations

    • Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090 Vienna, Austria
    • ,
  • Peter Valent

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18–20, 1090 Vienna, Austria
    • ,
  • Giulio Superti-Furga

      Affiliations

    • Center for Molecular Medicine of the Austrian Academy of Sciences, Lazarettgasse 19, 1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 1 40160 70001; fax: +43 1 40160 970000.

Received 3 June 2008 ,Revised 15 July 2008 ,Accepted 16 July 2008.

References 

  1. Adam M, Pogacic V, Bendit M, Chappuis R, Nawijn MC, Duyster J, et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. Cancer Res. 2006;66:3828–3835
  2. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007;25:1035–1044
  3. Bilban M, Heintel D, Scharl T, Woelfel T, Auer MM, Porpaczy E, et al Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia. 2006;20:1080–1088
  4. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U.S.A. 2005;102:11011–11016
  5. Chen XP, Losman JA, Cowan S, Donahue E, Fay S, Vuong BQ, et al. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc. Natl. Acad. Sci. U.S.A. 2002;99:2175–2180
  6. le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Blood. 2008;111:1834–1839
  7. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–2653
  8. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3
  9. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006;355:2408–2417
  10. Fukada T, Tonks NK. The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTP1B promoter in response to the p210 Bcr–Abl oncoprotein–tyrosine kinase. J. Biol. Chem. 2001;276:25512–25519
  11. Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, et al The Btk tyrosine kinase is a major target of the Bcr–Abl inhibitor dasatinib. Proc. Natl. Acad. Sci. U.S.A. 2007;104:13283–13288
  12. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma. 2008;49:615–619
  13. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y, et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood. 2006;107:4898–4906
  14. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15
  15. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood. 2007;109:5143–5150
  16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408
  17. Mishra GR, Suresh M, Kumaran K, Kannabiran N, Suresh S, Bala P, et al Human protein reference database—2006 update. Nucleic Acids Res. 2006;34:D411–D414
  18. Nunoda K, Tauchi T, Takaku T, Okabe S, Akahane D, Sashida G, et al. Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors. Oncogene. 2007;26:4179–4188
  19. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr. Opin. Genet. Dev. 2006;16:92–99
  20. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 2007;6:834–848
  21. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer. 2005;5:172–183
  22. Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib reveal novel kinase and non-kinase targets. Blood. 2007;110:4055–4063
  23. Rot A, Hub E, Middleton J, Pons F, Rabeck C, Thierer K, et al. Some aspects of IL-8 pathophysiology. III: Chemokine interaction with endothelial cells. J. Leukoc. Biol. 1996;59:39–44
  24. Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005;26:136–140
  25. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247–254
  26. Stuart JR, Kawai H, Tsai KK, Chuang EY, Yuan ZM. c-Abl regulates early growth response protein (EGR1) in response to oxidative stress. Oncogene. 2005;24:8085–8092
  27. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 2001;98:5116–5121
  28. Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leukemia Res. 28. Suppl. 2004;1:S21–S28
  29. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer. 2007;7:345–356
  30. Wong S, Witte ON. The BCR-ABL Story: Bench to bedside and back. Annu. Rev. Immunol. 2004;22:247–306
  31. Ye D, Wolff N, Li L, Zhang S, Ilaria RL. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood. 2006;107:4917–4925

PII: S1574-7891(08)00093-8

doi: 10.1016/j.molonc.2008.07.003

Molecular Oncology
Volume 2, Issue 3 , Pages 272-281 , October 2008

Article Tools

* Image Usage & Resolution